Fig. 1From: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational seriesSerum CA125 level in three patients with low tumor load. (The baseline of CA125 was used as the reference value, and all data were converted to natural logarithm.)Back to article page